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Background: Hepatic encephalopathy (HE) is a severe complication in patients with hepatic cirrhosis, which causes
numerous hospital admissions and deaths. Antibiotics are the best options in HE treatment, but head-to-head
comparisons between these drugs are scarce. Erythromycin combines the antimicrobial effect and prokinetic
properties in the same drug, but it has never been used in HE treatment. Our aim was to evaluate the efficacy of
erythromycin as an HE treatment.
Methods: We achieved a randomized controlled trial of adult patients with HE and hepatic cirrhosis admitted in
our hospital. After randomization, the subjects received either erythromycin 250 mg or neomycin 1 g orally QID
until hospital discharge or prescription of another antibiotic. All subjects were blindly evaluated every day towards
quantifying clinical, neuropsychometric, hepatic and renal exams. Statistical analysis was employed to compare the
groups and correlate the variables with hospitalization duration.
Results: 30 patients were evaluated (15 treated with each drug). At hospital admission, the groups were
homogeneous, but the erythromycin group subjects achieved a shorter hospitalization stay (p = 0.032) and a more
expressive reduction in alanine aminotranspherase levels (p = 0.026). Hospitalization duration was positively
correlated with C reactive protein levels measured previous to (p = 0.015) and after treatment (p = 0.01).
Conclusions: In the sample evaluated erythromycin was associated with significant reductions in hospital stay and
in alanine aminotranspherase values. Hospitalization time was positive correlated with C reactive protein levels
measured before and after the treatments.
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Hepatic encephalopathy (HE) is one of the major com-
plications in patients with hepatic cirrhosis, and plays a
crucial role in the prognosis. The prevalence of HE
among cirrhotic patients is 30-70% according to the
diagnostic criteria of overt or subclinical stages, whereas
in decompensated cirrhosis the estimated incidence is
8% per year [1-3].* Correspondence: fgromeiro@gmail.com
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reproduction in any medium, provided the orThe occurrence of HE is debilitating and frequently
results in hospitalization. In an observational study, 80%
of HE episodes were received in emergency care services,
and the mean hospitalization duration was between 5.7
and 7.1 days [1]. Furthermore, HE is not completely
reversible in some patients, given that multiple bouts of
hepatic coma constitute the only known risk factor that
triggers the acquired hepatocerebral degeneration, with
features suggesting toxic exposure to the brain [4].
In recent decades no major breakthrough in HE therapy
has been achieved [5]. Promising results concerning benefit
versus risk of antibiotics use are the most favorable [6,7].
Oral antibiotics that present low absorption can reduce
the small intestinal bacterial overgrowth (SIBO) which isl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reason, antibiotics can be particularly useful in emergency
settings to control ammonia production, but head-to-head
comparisons in HE treatment are scarce.
Nevertheless, antibiotics commonly used in the manage-
ment of HE or of intestinal bacterial illnesses play no role
in motility patterns or transit time. Cirrhotic patients
present many intestinal motility disorders with longer
transit times when compared to normal subjects. It has
been accepted that treatment with prokinetic drugs or anti-
biotics could improve not only the motility patterns, but
also the intestinal transit, SIBO and liver function [10-12].
Erythromycin is a macrolide antibiotic that can achieve
two potential targets in patients with liver cirrhosis: to
reduce the intestinal bacterial overgrowth and to
reorganize motility and transit time. Hence, this drug
could be used to decrease the ammonia production not
only in the colon but also in the small intestine, where
ammonia production can occur more rapidly than in the
colon in experimental studies [13]. Erythromycin estolate
seems to present some advantages over the other forms
[14-16] and was already evaluated in cirrhotic patients, but
only at the dosage of 500 mg QID, showing no deleterious
effects [17]. Minor dosages have been used as a prokinetic
drug for many years, and the risk of inducing bacterial
resistance is still not proven [18].
The purpose of this study was to provide a head-to-
head comparison between erythromycin and neomycin
in cirrhotic patients admitted to our hospital for an
acute episode of HE.
Methods
This study was approved by the local Ethics Committee
and carried out according to the Declaration of Helsinki
and its revisions. Informed consent was obtained.
Patients
Thirty adult patients with confirmed diagnosis of cirrhosis
and HE who had been admitted to our hospital during
a two-year period between May 2008 and April 2010
participated in the study. Exclusion criteria were: severe
infections, gastrointestinal bleeding, cancer, neuro-
psychiatric diseases, intestinal obstruction, shock, renal
insufficiency (basal serum creatinine level > 2.5 mg/dl),
alcohol abuse in the last six weeks, use of lactulose or
any antibiotic in the preceding seven days (except as
prophylactic prescription).
Protocol
All patients received initial care focused on the pre-
cipitating factors of HE: intravenous fluids (NaCl 0.9%
to achieve a urinary output above 0.5 ml/kg/h), enemas
when intestinal constipation was present, and correction
of electrolyte imbalances diagnosed upon hospital arrival.Subsequently, they were randomly assigned 1:1 to receive
either erythromycin estolate (EritrexW – Aché, Brazil)
250 mg QID or neomycin (Pharma Nostra Comercial
LTDA, Brazil) 1000 mg QID. Both drugs were administered
orally or, when necessary, through a nasoenteric tube. The
drugs were maintained until hospital discharge or the
prescription of another antibiotic.
During the hospital stay each patient was managed
while remaining blinded to the antibiotic treatment.
When the subjects were unable to take the antibiotics a
nasoenteral tube was inserted and the medications were
administered through it. The tube was removed as soon
as the patients were able to eat and drink safely. The diet
was the same in both groups during the study. All the
subjects were submitted to daily clinical exams, and to
neuropsychometric and blood tests. The study flow is
showed in Figure 1.
HE grading was made according to the West Haven
criteria. Supplementary data were used to grade the
Glasgow coma scale, flapping tremor, serum ammonia,
C reactive protein (CRP), alanine aminotranspherase
(ALT), aspartate aminotranspherase (AST), gamma-
glutamyl transpeptidase (GGT), alkaline phosphatase
(AP), urea, creatinine, and the number connection test
(NCT).
The laboratory exams were performed on venous
blood samples, and the ammonia quantification was
made in a strict protocol: all the individuals were
submitted to the same phlebotomy technique after an
overnight fasting. The samples were collected, briefly
maintained in a cooled recipient and immediately
transported on ice to the laboratory analysis. The
patients were not allowed to smoke for 8 hours before
the phlebotomy. To additional comparisons between
the groups, the hepatic encephalopathy index (HEI) was
calculated according to previous studies, in which HEI =
(HE grade x 3) + (flapping grade) + (neuropsychometric
test grade) + (ammonia level grade) [19,20]. The endpoint
was the hospital discharge and the results were analyzed
by intention to treat.
Statistical analysis
The results were presented as mean ± standard deviation
when they showed a normal distribution and as median
(first and third quartile) when not normal. Student’s t-test
and Mann–Whitney test were used to compare the groups.
Cirrhosis etiology, HE precipitating factors and HE classifi-
cation (episodic or persistent) in the two groups were com-
pared by Z score. The correlations between the number of
in-hospital days and the other variables were measured by
the Spearman rank correlation. All the data were analyzed
in SigmaStat version 3.5 (Dundas software LTD, Germany)
and Origin version 8.0 (OriginLab Corporation, USA). A
5% significance level was adopted.
Figure 1 Flow diagram of patients included.
Table 1 Comparison of HE-precipitating factors between
groups at hospital admission
Precipitating factor ERY NEO Total p*
Dehydration 3 4 7 (23.0%) 1.000
Undetermined 4 3 7 (23.0%) 1.000
Hyponatremia 2 4 6 (20.0%) 0.648
Intestinal constipation 2 1 3 (10.0%) 1.000
Animal protein overload 1 1 2 (0.7%) 0.591
Urinary infection 2 0 2 (0.7%) 0.466
Benzodiazepine use 1 1 2 (0.7%) 0.591
Hypokalemia 0 1 1 (0.3%) 0.992
Total 15 15 30 (100.0%)
ERY= erythromycin group. NEO= neomycin group. * = Z test comparison.
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Five of the thirty-five patients initially enrolled were
excluded, mainly for infections diagnosed after the hospital
admission (Figure 1). Eighteen men and twelve women
composed 60% and 40% of the included individuals,
respectively. According to the West Haven criteria, the
sample contained ten subjects with HE grade 1, nine with
grade 2, nine with grade 3 and two with grade 4. Sixteen
individuals had ascites (9 in the erythromycin group and 7
in the neomycin group). The need of tube feeding was not
different between the groups (4 subjects in each group).
The major etiology of cirrhosis in the sample was alcohol
abuse (six subjects in each group). In seven individuals the
cirrhosis etiology was not diagnosed (4 in the NEO group
an 3 in the ERY group). Viral hepatitis was present in
4 subjects in the NEO group and 3 in the ERY group
(six subjects presented hepatitis C and one had hepatitis
B). Autoimmune hepatitis was diagnosed in 3 individuals
(2 in ERY group and 1 in NEO group), and 1 subject
presented alpha-1 deficiency (ERY group). The clinical
and laboratory characteristics of each group are presented
in Tables 1 and 2. There were no significant differences
between the groups before HE treatment. The most
common precipitating factors were dehydration and
hyponatremia (Table 1).The results of each treatment were assessed by calculat-
ing the differences between the final and the initial values
of scores and exams, and are presented in Table 3. When
compared to the neomycin group, the erythromycin group
achieved a significant reduction in ALT levels (p = 0.026)
and in hospitalization duration (p = 0.032).
The correlations between the hospital stay and the
variables evaluated at emergency care admission are
presented in Table 4. Glasgow coma scale, HE index, HE
Table 2 Comparison of clinical and laboratory findings
between groups at hospital admission
Initial variables Erythromycin Neomycin p
Episodic HE1 4 7 0.449
Persistent HE1 11 7 0.263
Non classified HE1 0 1 0.992
Age (years) 2 55.20 ± 13.51 58.80 ± 10.47 0.421
Child-Pugh score 3 8.00 (8.00 : 10.50) 9.00 (8.00 : 10.75) 0.421
MELD score 2 16.40 ± 3.89 15.22 ± 4.40 0.440
HEG (grades) 3 2.00 (1.00 : 2.75) 2.00 (1.00 : 3.00) 0.421
HEI 3 13.00 (10.00 : 16.50) 14.00 (9.00 : 18.00) 0.588
GCS 3 14.00 (13.00 : 14.00) 13.00 (10.25 : 14.75) 0.394
CRP 3 0.80 (0.35 : 2.325) 1.40 (0.50 : 3.80) 0.475
NH3
3 96.00 (80.75 : 118.50) 82.00 (45.50 : 174.75) 0.468
Child-Pugh score = Child-Pugh modified classification. HEG = hepatic
encephalopathy grades. HEI = hepatic encephalopathy index. GCS = Glasgow
coma scale. CRP = C reactive protein (mg/dl). NH3 = serum ammonia (μM/l).
1
absolute values and Z score comparison; 2 mean ± standard deviation and t test
comparison ; 3 median, 1º : 3º quartiles and Mann–Whitney test comparison.
Table 4 Correlations between in-hospital days and other
variables at admission
Variables GCS MELD HEI HEG CRP NH3
IHD (R) −0.480 −0.040 0.440 0.526 0.454 0.120
IHD (p) 0.007 0.840 0.015 0.028 0.015 0.520
IHD (R) = Spearman rank correlation coefficient with in-hospital days. IHD (p) =
p value of the Spearman rank correlation with in-hospital days. GCS = Glasgow
coma scale. HEI = hepatic encephalopathy index. HEG = hepatic encephalopathy
grade. CRP = C reactive protein (mg/dl). NH3 = serum ammonia (μM/l).
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with the hospitalization duration.
The correlations between the length of the hospital
stay and the variations in C reactive protein levels
obtained during the treatment are presented in Figure 2.
The CRP levels were significantly correlated and varied
directly with the number of in-hospital days.Table 3 Comparison of the results obtained with each
treatment during the hospitalizations
Variables Erythromycin Neomycin p
Δ IHD 1 3.00 (2.25 : 4.00) 5.00 (3.25 : 11.25) 0.032
Δ GCS 1 1.00 (0.25 : 2.00) 0.00 (0.00 : 3.25) 0.394
Δ MELD 2 −0.55 ± 1.53 −0.62 ± 2.08 0.917
Δ HEG 1 2 (1 : 2.5) 2 (1 : 3) 0.806
Δ HEI 1 −6.00 (−9.00 : -1.50) −5.00 (−7.00 : -1.25) 0.632
Δ CRP 1 0.30 (0.10 : 0.70) 1.10 (0.15 : 4.30) 0.111
Δ NH3
2 −31.40 ± 49.32 −30.70 ± 92.15 0.979
Δ ALT 2 −3.20 ± 8.54 3.71 ± 7.12 0.026
Δ AST 2 −15.70 ± 48.06 8.42 ± 21.80 0.678
Δ AP 2 −17.70 ± 65.3 −12.30 ± 48.90 0.802
Δ GGT 1 −7.00 (−29.00 : 0.75) −5.00 (−25.50 : 5.00) 0.724
Δ urea 2 −2.19 ± 20.64 −4.25 ± 23.72 0.802
Δ creatinine 2 −0.10 ± 0.27 −0.20 ± 0.30 0.289
1 median, 1º : 3º quartiles ; Mann–Whitney test comparison.
2 mean ± standard deviation ; t test comparison.
Δ = final – initial values. IHD = in-hospital days. GCS = Glasgow coma scale.
HEI = hepatic encephalopathy index. HEG = hepatic encephalopathy grade.
CRP = C reactive protein (mg/dl). NH3 = serum ammonia (μM/l). ALT = alanine
aminotranspherase, AST = aspartate aminotranspherase, AP = alcaline
phosphatase, and GGT = gamma-glutamyltranspeptidase (all in U/l). Urea and
creatinine are measured in mg/dl.Descriptive findings
Although the sample in this study was composed of sub-
jects with advanced cirrhosis, no adverse effects related
to the antibiotics were observed. Only three subjects in
the erythromycin group and six in the neomycin group
had worsened their MELD scores during the treatment,
with a maximum increase of 2.4 points. Two elderly
individuals had acute renal injury during the study, both
in the neomycin group, but in neither case was this
complication attributed to the antibiotic used.
The final analysis was performed by intention to treat,
but only four patients had their medications discontinued
due to infection signals, which led to a shift to other
antibiotics. These cases belong to the neomycin group,
and they all had received the drug for at least 24 hours.
Three had pneumonia and one presented a urinary
infection. In color Doppler ultrasound exams, two subjects
displayed signs of portal vein thrombosis and two had
splenorenal shunts (one in each group in both diagnoses).
Although 16 subjects had ascites there were no spon-
taneous bacterial peritonitis during the trial.
Only two patients were transferred to intensive care
units, both in the neomycin group. There were two
deaths during the study, also in this group, but theFigure 2 Correlation between in-hospital days (IHD) and C
reactive protein (CRP) variation. CRP variation in each subject was
calculated by subtracting the initial CRP from the final CRP value.
Spearman rank correlation coefficient (R) = 0.51 and p = 0.01.
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occurred.
Three subjects in the erythromycin group and five in
the neomycin group did not reach fifteen points on the
Glasgow coma scale until hospital discharge. Excluding
the two deaths in the neomycin group, two cases in each
group were persisting in an alert pattern lower than the
fifteen points in the Glasgow coma scale (before and
after hospital admission).
Until January 2012, sixteen subjects were still alive, ten
had died and four missed the follow-up. Only the
younger subject in the study was submitted to liver
transplantation after an episode of spontaneous bacterial
peritonitis. Currently, none of them are on a transplant
waiting list. Only one patient was submitted to
embolization of a splenorenal shunt after several episodes
of hepatic coma. The second subject suffering from this
condition is still waiting for this procedure. One patient
developed hepatocellular carcinoma and was submitted to
transarterial chemoembolization to future inclusion in a
liver transplant list. The main causes of death during the
follow up were related to infections.
Discussion
Our study has shown for the first time that erythromycin
can be employed as a feasible HE treatment in cirrhotic
patients. The drug has been used as an antibiotic for
almost five decades and as a prokinetic for more than ten
years, even in ICU patients, pregnant women and
children. Its antibiotic and prokinetic effects appear to be
very promising in patients with HE and cirrhosis. Our
results showed significant reductions of the hospitalization
duration and also of the ALT levels in patients that have
been treated with erythromycin.
The use of a placebo in severe cases of HE is unjustified,
and in HE treatment trials comparisons with disaccharides
as controls are not adequate [7,21]. Thus, the comparison
with another antibiotic enabled the correlation of our
results with many other studies. We emphasize that the
control group received the maximum secure doses of
neomycin [2].
The most prevalent cause of cirrhosis was alcohol and
the major precipitating factors were dehydration and
hyponatremia, as found in other similar trials [19,22].
Most of the patients had persistent HE, and among these
subjects we had some difficulty to determine the precipi-
tating factor involved, as mentioned by other authors
[23]. Besides the fact that MELD scores and Child-Pugh
classifications were high, they were not correlated with
the total in-hospital days, while the MELD score seems
not to be associated with HE severity, as reported by
other authors evaluating the renal function in similar
patients [24]. This particular discrepancy between HE
severity and MELD score appears to account for the lowrates of liver transplantation in these patients, and could
contribute to the high mortality rates caused by HE.
HE index and HE grade showed similar results, because
neither ammonia levels determination nor common
psychometric testing were helpful for HE grading, as
already noticed by other authors [20,25,26]. As the sample
was composed by many patients with severe HE, they
could not collaborate properly to be submitted to other
specific exams. The only way to quantify their treatment
response was the clinical findings according to the West
Haven criteria.
In relation to applicability, our sample was formed by
subjects with more severe HE than in other studies
(nine patients with HE grade 2, nine with grade 3 and
two with grade 4), which is an important concern in HE
trials. The option of using a new drug requires a close
observation of these patients and the possibility of
antibiotic switch in case of infections. Also of interest
are the hospitalization duration as the study endpoint
and its correlations with clinical and laboratory variables.
Thus, the correlation of the number of in-hospital days
with HE grade, IEH, GSC and CRP showed simple clinical
aspects that could to estimate the time of HE recovery
during which these patients are treated with antibiotics.
Since the median in-hospital stay obtained in our trial
was 5.6 days, very similar to the value found in an
observational North American survey, our results
would be reproducible in clinical practice [1].
The high correlation obtained between CRP levels and
the total in-hospital days corroborates the impact of the
systemic inflammatory status not only at the moment of
hospital arrival, but also as an indicator of HE regression
during the treatment with antibiotics. This finding is
new and can be used to check the response to the
treatment. Another study correlates the CRP levels
with encephalopathy occurrence in cirrhotic patients, and
many others have described the relevance of inflammation
in HE neural physiopathology [24,27,28]. Nevertheless, this
is the first time that CRP levels are correlated with the
hospitalization duration. The role of inflammatory cyto-
kines in affecting the blood–brain barrier and increasing
the ammonia diffusion in astrocytes was also well described
by other authors [29]. By associating these reports with our
findings, we postulate that the CRP reduction must be a
clinical target during antibiotic treatment in HE when the
values obtained are high.
As also described previously, the selective decontamin-
ation of the small intestine in these patients promotes the
recovery of motility and the control of bacterial products
released in the blood [10,30]. Consequently, the use of
prokinetics, antibiotics or probiotics can be indicated as a
direct treatment against SIBO and gut dysmotility [31].
Erythromycin is a drug that combines the prokinetic and
antibiotic effects to enable synergistic action in the
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of intestinal bacterial overgrowth, but the ALT reduction
can be considered an indirect indicator of the role of
erythromycin in preventing the release of these bacterial
products into the portal vein. According to previous
studies, these patients have an increase in production and
absorption of intestinal bacterial products, which can lead
to a continuous flux of lipopolysaccharides and other toxic
materials to the portal vein. In the liver, these substances
are recognized by Kuppfer cells and thus trigger the
release of tumor necrosis factor (TNF), which together
with other products of these cells, leads to hepatocyte
lesion [32,33]. Given that continuous hepatocyte injuries
are a source of ALT elevations, we hypothesize that the
decrease in the efflux of bacterial products to the liver and
the control in systemic inflammation caused by them may
have been the key to achieving the promising results
obtained by erythromycin in this trial. To avoid inter-
laboratory fluctuations, we use the differences between the
final and initial ALT and CRP levels as indirect tools to
document these plausible mechanisms, which could be
the reason for the improvement in hepatic function
obtained in other studies by the long term use of antibiotics
and prokinetics in cirrhotic patients [10].
Not only SIBO must be discussed as an oligosymptomatic
cause of HE, but other bacterial infections in cirrhotic
patients might be important, as Helicobacter pylori infec-
tion. H. pylori infection can produce high blood ammonia
concentration in these patients, and the eradication of this
pathogen may be helpful for treatment and prevention of
HE [34]. In this study, the subjects were not submitted to
H. pylori tests, but the role of erythromycin could be
important in infected patients. In contrast, neomycin is
probably useless against bacterial infections in the stomach.
Motility disturbances are clearly associated to cirrhosis,
but the subjects evaluated in this study were not submitted
to motility exams. Some patients could have a better effect
of erythromycin than others, and this information is
important in view of future uses of erythromycin in patients
with HE. According to the good results obtained with
prokinetics in cirrhotic patients, erythromycin must be
evaluated in other studies about this condition [10-12].
Hence, given that antibiotics are already considered
the best options for HE treatment and that the new
drugs are still not useful in clinical practice, our proposal
is very attractive because erythromycin is well known,
easy to administer and less expensive than other treatments
[23]. We hope that new studies can confirm the security
profile of this dosage in cirrhotic patients.
Conclusion
In conclusion, the use of erythromycin in HE patients
achieved reductions of both hospitalization length and
ALT levels when compared to neomycin. Additionally,the length of hospitalization caused by HE was positively
correlated with CRP levels measured before and during
the antibiotic treatment. There were no adverse events
that could be related to the drugs utilized, even in
patients with advanced liver disease, but the latter finding
needs to be confirmed in future studies.
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